Background: Matrix metalloproteinase (MMP) 14 may mediate tumor progression through vascular and immunemodulatory effects.
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Matrix metalloproteinases (MMPs) facilitate cancer progression (1) (2) (3) . However, broad-spectrum MMP inhibitors failed in part because MMPs mediate both pro-and anticancer effects (4-7) and because off-target, dose-limiting toxicity impeded efficacy (7) . To counter these deficiencies, agents targeting specific MMPs have been developed. For breast cancer (BC), MMP14 (membrane type 1-MMP; MT1-MMP) is an especially attractive target (2, 8) . Genetic knockdown of MMP14 in BC cells impedes their migration and metastases but does not affect their in vitro viability or primary tumor growth (3, 8) . In contrast, antibody inhibition-which blocks both cancer and stromal MMP14 activity-slows primary tumor growth (9, 10) . Indeed, a considerable number of reactive stromal cells also express MMP14 (2) , illustrating the potential importance of stromal MMP14.
MMP14 facilitates angiogenesis (11) (12) (13) , and MMP14 blockade can inhibit tumor angiogenesis (9, 10) . Various antiangiogenic agents, however, can also transiently normalize the tumor vasculature, improving tumor perfusion and oxygenation, leading to enhanced efficacy of chemo-and/or radiation-therapy (14) (15) (16) . In preclinical models, blockade of MMP14 could enhance the response to cytotoxic therapies (9, 10) . These findings prompted us to determine a potential improvement in tumor vascular function by MMP14 blockade.
The antiangiogenic effect of MMP14 inhibition is thought to result from reduced activation of MMP2 by MMP14 (9) . However, other MMP14 targets have not been studied, including transforming growth factor β (TGFβ), a mediator of vascular response and a potent immunosuppressor. TGFβ is associated with poor clinical outcome in BC (17) . TGFβ has proangiogenic activities and mediates vessel stabilization (18) (19) (20) . TGFβ inhibitors increase antitumor immunity associated with increasing interferon (IFN)-γ and granzyme B production from natural killer (NK) cells and cytotoxic CD8
+ T cells, reducing T regulatory cells, and shifting macrophages toward an inducible nitric oxide synthase (iNOS)-expressing antitumor M1-like phenotype and away from tumorsupportive M2-type (21) (22) (23) (24) (25) (26) (27) .
In this study we investigated if DX-2400 (9), a highly selective MMP14 inhibitory antibody, could decrease TGFβ levels and alter the macrophage phenotype in tumors. We also aimed to determine if DX-2400 could improve tumor vessel function and thus provide additional benefits when combined with radiation therapy.
Methods

Tumor Models
All animal procedures followed Public Health Service Policy on Humane Care of Laboratory Animals guidelines and were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee. A single 4T1 primary tumor per mouse was established by implanting 1x10 5 cells into the third mammary fat pad (MFP). As previous studies using anti-MMP14 antibodies employed NU/NU (nude) mice (9,10), we also used female (age six to eight weeks) nude mice to assess if macrophages were capable of responding to DX-2400 in the absence of adaptive immunity. We then confirmed key findings in immunocompetent C57BL/6 mice bearing syngenic E0771 tumors. E0771 tumors were established by implanting 2x10 5 . Control IgG or DX-2400 was injected at an established effective dose (10 mg/kg) every 48 hours i.p. (9) . Treatment continued for a maximum of 10 injections. Local radiotherapy began four days after tumors reached approximately 40 mm 3 (ie, equivalent to day 4 of DX-2400 or IgG treatment). Fractionated irradiation was given using XRAD 320 irradiator (Precision X-Ray, Inc.) at 3.5 Gy/min to a total dose of 6 Gy per daily fraction on three consecutive days. A selective iNOS inhibitor (1400W dihydrochloride, Enzo Life Sciences) was delivered by s.c. osmotic minipump (Alzet 1002; 0.42 mg/kg/hour).
Immunostaining
Details are provided in the Supplementary Methods (available online). Primary antibodies included: MMP14, cluster differentiation factor 31 (CD31, endothelial cell marker), NG2 (pericyte marker), Collagen IV (basement membrane (BM) marker), iNOS-FITC, CA9 (hypoxia marker), HSP90, SMAD2/3, F4/80-Cy5 (macrophage marker), mannose receptor C type 1 (MRC1, M2 marker), granzyme B (cytotoxic activity marker), NK1.1-Cy3 (NK cell marker), proliferating cell nuclear antigen (PCNA, proliferation marker), and Apoptag (apoptosis marker).
Optical Frequency-Domain Imaging
Optical Frequency-Domain Imaging (OFDI) allows detailed analysis of the geometry and functionality of the perfused tumor vasculature (28) . OFDI was performed at day 4 using a custom-built microscope as described previously (28) . Additional details are provided in the Supplementary Methods (available online).
Western Blotting and Antibody Array
Details are provided in the Supplementary Methods (available online). Protein was collected from tumors following six days of treatment. Primary antibodies included MMP14 (Abcam, ab51074, 1:1000), iNOS (BD Biosciences, 610329, 1:500), TGFβ (Cell Signaling, 3711S, 1:1000), and β-actin (Sigma, A5441, 1:5000). The antibody array (RayBiotech, AAM-INF-1) protocol followed manufacturer's instructions.
Image Analysis
Details are provided in the Supplementary Methods (available online). Quantification of staining was performed using an inhouse MATLAB (MathWorks) segmentation algorithm or ImageJ (29) . Relative densitometry was determined using ImageJ with normalization to the loading control.
Statistical Methods
PRISM (GraphPad Software, version 6e) and Statistical Analysis System (SAS) 9.4 were used for analyses. All statistical analyses between two groups were performed using the nonparametric Mann-Whitney test. However, when more than two groups were assessed, following confirmation that normality was achieved (using Kolmogorov-Smirnov test in PRISM), data were assessed by analysis of variance (ANOVA) followed E.I. Ager et al. | 3 of 12 article by Bonferroni adjusted post hoc t tests for multiple pairs of interest without a priori selection. Robust regression and outlier removal (ROUT, GraphPad) was used to determine if outliers were present. All statistical tests were two-sided. A mixed model was fitted to test the differences between treatment and control tumor growth curves accounting for repeated measurements over time and mouse as a random effect. Differences were considered statistically significant at P values of less than .05; P values between .05 and .1 were considered to show a trend and are also presented in figures. Data are presented as median with the interquartile range and, in the case of boxplots and column graphs, maximum and minimum values.
Results
MMP14 Expression in Murine BC Models
We determined MMP14 protein expression in 4T1 and E0771 BC cells in in vitro culture and in tumor tissues in vivo ( Figure 1A ). Although MMP14 protein was detected in both BC models, 4T1 tumors express a notably higher level of MMP14 compared with E0771. We confirmed that MMP14 was membrane associated in these models ( Figure 1B ). We then costained for MMP14 and F4/80 and discovered that essentially every macrophage expressed MMP14 ( Figure 1 , C and D), thus showing that MMP14 may not be differentially expressed by M1-and M2-type macrophages.
Efficacy of anti-MMP14 antibody (DX-2400) in vivo and in vitro. We confirmed that DX-2400 treatment reduced collagenolytic activity, a readout of MMP14 activity, in 4T1 tumors effectively in vivo (P = .0457) (Figure 1 , E and F). We also confirmed that DX-2400 treatment of 4T1 cells in vitro did not affect cell viability ( Figure 1G ), but it statistically significantly inhibited cell invasion through a collagen matrix in a dose-dependent manner (P = .0314 with DX-2400 at 0.2 µg/mL to P = .0004 following DX-2400 at 100 µg/mL treatment) ( Figure 1H ).
Effect of Anti-MMP14 Treatment on BC Growth
Monotherapy with the anti-MMP14 antibody (DX-2400) statistically significantly delayed both 4T1 and E0771 tumor growth. A mixed model indicated a statistically significant reduction in tumor growth rate following DX-2400 treatment in both tumor models (P < .001 for both models) ( Figure 2 , A and B; Supplementary Figure 1 , A and B, available online). Subsequent analysis of each individual time point indicated that this divergence in tumor growth was statistically significant from day 6 onwards (4T1, P = .0028, CT 279.9 mm 3 ± 117.7, DX 128.4 mm 3 ± 51.2; E0771, P = .017, CT 144.9 mm 3 ± 57.4, DX 78.14 mm 3 ± 46.5; mean ± SD). Consistent with reduced 4T1 growth, there was a trend for increased apoptosis at day 4 and necrosis at day 10 (P = .0606 and P = .0590) ( 
Effect of MMP14 Blockade on Tumor-Associated Macrophages
Given the early (day 4) reduction in proliferation and subsequent tumor growth delay, we aimed to determine if the tumor microenvironment was also altered by treatment at this stage. In 4T1 BC, DX-2400 led to a modest increase in F4/80 + cell numbers at day 4 (P = Figure 4J , available online). Collectively, we found that MMP14 blockade shifts immune cell and cytokine profiles from immunosuppressive to antitumor phenotype in our BC models.
Effect of MMP14 Inhibition on BC iNOS Expression
While assessing iNOS as an M1 marker, we also noted a statistically significant increase in gross tumor-associated iNOS in the 4T1 tumors following DX-2400 treatment (P = . (31, 32) and presumably facilitates increased iNOS levels in 4T1. Moreover, the increase in IFNγ seen in the antibody array could also increase tumor iNOS expression (33,34).
Effect of Anti-MMP14 Antibody Treatment on Tumor Vasculature
To investigate DX-2400-associated changes in the tumor vascular geometry and function, we used a robust noninvasive imaging technique, OFDI, which specifically visualizes perfused (containing moving red blood cells) vessels. We found a statistically significant increase in the total number of perfused vessels with DX-2400 treatment (P = .0205, CT 73 vessels/ 
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CT DX treatment at day 4 (C; high-frequency Apoptag staining assessed as greater than 10 apoptotic cells per field of view) and, similarly, necrosis tended to be greater in day 10 samples from DX-2400 treated animals. E-F) Cell proliferation. Day 4 proliferation (proliferating cell nuclear antigen) was decreased by DX-2400 (E), while day 10 proliferation showed a trend (F). Images of Apoptag, necrosis, and PCNA are provided in Supplementary Figure 2 (available online). All data from panels C to F were obtained from 4T1 tumors in nude mice. Data are presented as median with the interquartile range (box) and maximum and minimum values (whiskers) for panels C to F. P values determined by two-sided Mann-Whitney test. Samples sizes: n = 6 for all analyses except day 10 necrosis (n > 8) and tumor growth curves (n = 10 for 4T1 and n = 7 for E0771). CT = control; DX = DX-2400; FoV = field of view; HI = high-frequency; PCNA = proliferating cell nuclear antigen. Figure 5F ; Supplementary Figure 10 , available online). NO, a potent vasodilator, is an important regulator of vessel function (38) . The increase in vessel diameter without changes in the number of endothelial cells (CD31 positivity) suggests that functional vessel dilatation rather than hyper proliferation plays a key role in vessel diameter increase in this setting. Indeed, blockade of iNOS (by 1400W) prevented the DX-2400-induced improvement in perfusion and oxygenation ( Figure 5 , E and F). In E0771 tumors there was no statistically significant difference in hypoxia between DX-2400 and control ( Figure 5G ), possibly reflecting the lack of increased tumor iNOS in this model.
Effect of MMP14 Blockade and Radiation Combined Treatment
Radiation therapy, similar to DX-2400, delayed 4T1 tumor growth compared with control (days to grow to 800 mm Figure 11A , available online). The combination therapy resulted in superior growth inhibition compared with either monotherapy (P ≤ .0001), and this effect was greater than the expected additive effect (P = .054, and, confirmed in Figure 6F , P = .042), demonstrating synergy between these therapies. In E0771 tumors, identical radiation and DX-2400 treatments were also effective, but their combination led to an additive tumor growth delay only (P = .430) ( Figure 6 , C and D; Supplementary Figure 11B , available online).
To understand when DX-2400 and irradiation treatments interact and if this correlated with day 4 changes in tumor perfusion Figure 11D , available online), suggesting that iNOS contributes to the tumor growth delay benefit of adding radiation to DX-2400. These findings are consistent with the abrogation by 1400W of effects of DX-2400 on tumor perfusion and oxygenation ( Figure 5, E and F) .
The P values presented in Figure 6 were determined using ANOVA with Bonferroni adjustment (as the variables of interest fit the required normality assumption). It is worth noting that a Kruskal-Wallis analysis confirmed key findings: statistically significant reduction in tumor growth with DX-2400 (in the 4T1 model; P = .0243), statistically significant reduction in tumor growth upon combination treatment (in both models; 4T1 P < .0001, E0771 P = .0012), a statistically significant reduction in tumor growth compared with radiation alone only when DX-2400 was given before/during radiation (P = .0051 and .0037, respectively) but not after radiation (P = .8865), and reduced efficacy of the combination therapy when iNOS was blocked (tumor growth .0217
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.0190 DX on days 0, 2, and 4 with radiation on days 4, 5, and 6) and seven postirradiation injections (RDX). F) The effects of iNOS were assessed using 1400W in addition to DX (DXW), radiation (RW), and the combination (DXRDXW). The synergy associated with combination treatment in the 4T1 model was lost when iNOS was inhibited. Analysis of variance with Bonferroni post hoc t test was performed for analysis of tumor growth. All statistical tests were two-sided. Additional data are provided in Supplementary Figure 11 (available online). CT = control; DX = DX-2400; DXR = three initial injections of DX-2400 plus radiation; DXRDX = ten DX-2400 injections plus radiation; DXRDXW = combination DXRDX plus 1400W; DXW = DX-2400 plus 1400W; RDX = radiation followed by DX-2400; RW = radiation plus 1400W.
article reduction compared with control; P = .0001 for RDX compared with P = .0012 for RDXW).
Discussion
Here, we show that the treatment with highly selective MMP14 inhibitory antibody, DX-2400, was associated with the decrease in active TGFβ-an immunosuppressive cytokine-in murine BC tissue. Consistent with this, macrophages were shifted towards antitumor phenotype. Furthermore, we found that DX-2400 can increase vascular perfusion and reduce hypoxia in murine BC, resulting in synergistic therapeutic effectiveness of DX-2400 combined with radiation. We also found that iNOS appears to mediate these beneficial effects of MMP14 blockade in combination with radiation.
Inhibition of MMP14 has antiangiogenic effects when examined at late stages of tumor development (9, 10) . However, we show that vascular responses differ at earlier time points. Our findings demonstrate improved vascular function at day 4 following MMP14 inhibition that seems to be achieved through a reduction in vessel tortuosity and an increase in vessel diameter. We confirmed previous findings that antibody inhibition of MMP14 can slow primary tumor growth (9, 10) , suggesting that an antiangiogenic response is not required for the initial growth retardation from MMP14 inhibition, although it may contribute at later stages.
Typically, tumor-associated macrophages are polarized towards an M2-like state and provide support for tumor growth and progression (27, 39) . Consistent with the decrease in TGFβ, we discovered that DX-2400 induced M1-like macrophages that could contribute to primary tumor growth delay. We found that proliferation was reduced and necrosis increased. Activated NK cells can control tumor growth by inhibiting cellular proliferation and promoting apoptosis (40, 41) . TGFβ produced in the tumor stroma, however, leads to impaired NK cell function (40, 42) . In concordance with the reduction in TGFβ following DX-2400 treatment, we showed an increase in NK cells and granzyme B production with DX-2400.
The DX-2400-associated increase in iNOS at day 4 allied with an increase in vessel perfusion and a reduction in tumor hypoxia in the 4T1 model. Further, iNOS blockade prevented these vascular changes and resulted in the loss of synergy in combination with radiation. In the E0771 model, while macrophage numbers and macrophage-associated iNOS increased, tumor-wide iNOS expression and hypoxia were not substantially affected. This difference in response to DX-2400 is consistent with the failure of combination therapy to result in a more than additive benefit in the E0771 model but may also reflect differences in the power to assess these differences because of the reduced sample size of E0771 compared with the study using 4T1 tumors. The sample sizes chosen were based on tumor growth curves from earlier studies using these models and a preliminary study using DX-2400, but the strength of our conclusions would have benefited from additional animals at early time points in the 4T1 model and in studies using E0771 tumors. Biologically, 4T1 and E0771 tumors differ in several respects, including endogenous MMP14 and iNOS expression, and altered response to DX-2400 could also reflect a combination of these differences. Moreover, the control tumors also differ considerably in their microvascular densities (Supplementary Figure 12 , available online). Extravascular components are also important indirect regulators of vessel perfusion in solid tumors (43) (44) (45) . Reduction in solid stress, such as by tumor cell death, could open nonfunctional vessels and markedly increase tumor perfusion (44) . Another potential mechanism by which DX-2400 could increase article tissue oxygenation is through decreased oxygen consumption by cancer cells, an effect that iNOS could also mediate (46) .
Although radiation therapy is not widely used in the neoadjuvant setting for BC, we utilized it here for two reasons: 1) to evaluate the potential usefulness of MMP14 inhibition in other tumors for which radiation is more commonly utilized, and 2) to use radiation as an additional tool to evaluate DX-2400-induced changes in tumor oxygenation. The data obtained fulfill both purposes. The synergistic tumor growth delay achieved in the 4T1 model was modest, however. This is consistent with the relatively low average hypoxic fraction in control 4T1 tumors, approximatley 20% at day 4 by CA9 staining fraction. Given that a dose of 6 Gy of irradiation can kill approximately 70% of oxygenated 4T1 clonogenic cells in vitro (47) , each 6 Gy fraction used here would only eliminate aproximately 55% to 60% of all clonogenic 4T1 cells, and so even converting all hypoxic cells to oxygenated cells before irradiation would only decrease the survival fraction by a further 10% to 15%. Higher doses of radiation per fraction and/ or lower tumor oxygenation (ie, more hypoxic tumors) might be expected to result in greater synergy.
Inhibition of MMP14 slowed growth of BC in orthotopic murine models and improved their response to concurrent radiation therapy via improved tissue oxygenation ( Figure 7 ). We found a novel association between antibody inhibition of MMP14 and an antitumor shift in macrophages and tumor immunity that could contribute to tumor growth delay resulting from anti-MMP14 monotherapy. Moreover, the increase in MMP14 blockade-induced tumor iNOS led to improved vascular function and tissue oxygenation resulting in enhanced radiation response. These findings suggest MMP14 as a potential therapeutic target to modulate the tumor microenvironment and iNOS induction as a potential biomarker.
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